The Aperlena Verdict
Open raceNo supplier dominates: 12 different companies have won the last 13 comparable contracts from this buyer over 5 years. This is a genuinely open race.
Based on 13 comparable awards by this buyer in this sector over 5 years. Every verdict is recorded before the outcome and graded against the award notice. How we score ourselves.
Summary
Machine-generated summaryAOK Sachsen-Anhalt in Germany concludes non-exclusive rebate contracts under Section 130a (8) SGB V for finished medicinal products containing the active substance Pegfilgrastim (ATC: L03AA13) using an open-house model. All suitable and interested pharmaceutical companies or groups of pharmaceutical companies may join at any time under uniform contract conditions and a uniform access procedure, with no exclusivity and no individual negotiations. Contracts can start from 01.11.2026 and run for a maximum of 24 months, ending 31.10.2028. Interested companies must request participation documents and the contract from the contact address and return them fully completed and signed.
Description
Official source
Source: TED - Tenders Electronic Daily (Publications Office of the EU)
Always verify details on the official notice.
Last verified against TED - Tenders Electronic Daily (Publications Office of the EU) 1 week ago
More from this buyer
Full buyer profile56 open tenders right now
- Sports-related services - Prevention project 'Bewegter Hort' 20 days left
- Maintenance and repair of office machines - Framework contract for consumables, accessories and services for MFPs 20 days left
- Medicines - Medicines with the active substance combination Timolol and Latanoprost (ATC code S01ED61 - excluding standard pack sizes N1-N3) 461 days left
Who usually wins this buyer's contracts in this sector
| Company | Wins | Total awarded | Last win |
|---|---|---|---|
| Novartis Pharma GmbH | 2 | n/a | Sep 2026 |
| Bayer Vital GmbH | 1 | n/a | Sep 2026 |
| Biotest GmbH & Co. KGaA | 1 | n/a | Sep 2026 |
| CSL BEHRING GMBH | 1 | n/a | Sep 2026 |
| GlaxoSmithKline GmbH & Co. KG | 1 | n/a | May 2026 |
Based on 13 awards with a linked company profile over the last 5 years.
What this buyer has paid before
Based on 13 comparable contracts this buyer awarded in this sector over the last 4 years.
- €1
- Lower quartile
- €1
- Median award
- €1
- Upper quartile
Most recent awards
- Medicines - Rebate contract under Section 130a(8) SGB V in conjunction with Section 130c(1) SGB V for the medicines Esperoct (B02BD02), NovoEight (B02BD02) and Alhemo (B02BX10) for the treatment of haemophilia
- Medicines - Discount agreement under § 130a para. 8 SGB V i.V.m. § 130c para. 1 SGB V for the medicines Haemate P (B02BD06) and Voncento (B02BD06) for the treatment of haemophilia
- Pharmaceuticals - Discount agreement under Section 130a(8) SGB V in conjunction with Section 130c(1) SGB V for the medicinal product Factor VIII SDH (B02BD02) for the treatment of haemophilia
- Medicines - Discount agreement under § 130a(8) SGB V i.V.m. § 130c(1) SGB V for Haemoctin SDH (B02BD02) and Haemonine (B02BD04) for haemophilia treatment
- Medicines - Pharmaceutical discount contract under section 130a paragraph 8 SGB V in conjunction with section 130c paragraph 1 SGB V for the medicinal product Fanhdi (B02BD06) for the treatment of haemophilia
Award values as published by the official sources. Use them as a guide, not a rule: scope, lots and duration differ between contracts.
Similar tenders
2
days left
€2,750,000
est. value
Market context
- Avg. open tender · Medical equipment & pharmaceuticals
- €10,072,553
- Buyer track record on Aperlena
- 93 notices tracked · 36 awarded
- €2,700,013 in awarded contracts
Never miss a tender like this
76 new notices in Medical equipment & pharmaceuticals in Germany in the last 7 days. Get an email when new ones appear. Free.
Set up my alert